SGLT2 inhibitors have been proven to reduce glycated hemoglobin level by 0.7% to 1.0%.[3] Moreover, a recent large randomized controlled trial in patients with T2D showed that SGLT2 inhibitors reduce major adverse cardiovascular events in patients with established atherosclerotic cardiovascular disease, diabetic kidney disease, as well as hospitalization for heart failure.[4] Due to these positive effects, the use of SGLT2 inhibitors is expected to grow rapidly. The gene discussed is SLC5A2; the disease is heart failure.